Brexpiprazole (/brɛksˈpɪprəzoʊl/ breks-PIP-rə-zohl; also called OPC-34712) is a novel D2 dopamine partial agonist investigational product currently in clinical trials for the treatment of depression schizophrenia and attention deficit hyperactivity disorder (ADHD).
This page contains content from the copyrighted Wikipedia article "Brexpiprazole"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
